Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRONKODYL vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bronkodyl contains theophylline, a xanthine derivative. It acts as a bronchodilator by inhibiting phosphodiesterase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle. Additionally, it blocks adenosine receptors and may have anti-inflammatory effects.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
Theophylline extended-release: 300-600 mg orally every 12 hours; target serum concentration 5-15 mcg/m L.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Terminal elimination half-life is 3–8 hours in non-smoking adults, 1–5 hours in smokers, and 20–30 hours in premature neonates; clinical context: half-life increases in hepatic impairment, heart failure, and with certain medications (e.g., cimetidine, fluoroquinolones).
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily hepatic via cytochrome P450 enzymes, mainly CYP1A2 and CYP3A4. Metabolized to 3-methylxanthine, 1-methyluric acid, and 1,3-dimethyluric acid.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal: approximately 90% as theophylline and its metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid); biliary/fecal: <10%.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Approximately 40% bound to plasma albumin.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
0.3–0.7 L/kg; clinical meaning: distributes into total body water, with higher Vd in neonates and patients with hepatic cirrhosis.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral (immediate-release): 80–100%; oral (sustained-release): 80–100% (subject to first-pass metabolism); rectal: approximately 80%.
Oral: 40-50%; Inhalation: 20-30%
For GFR <30 m L/min: reduce dose by 50% and monitor serum levels; for GFR 30-60 m L/min: reduce dose by 25%.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75% or use alternative agent.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Loading dose: 5-7 mg/kg IV over 30 minutes; maintenance: 0.5-1 mg/kg/hour IV continuous infusion or 10-20 mg/kg/day orally divided every 8-12 hours; adjust to achieve serum levels 5-10 mcg/m L.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Start at lower end of dosing range (300 mg/day) and titrate slowly; monitor serum theophylline levels closely due to reduced clearance.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
No FDA black box warning.
No FDA black box warning.
Risk of toxicity due to narrow therapeutic index; monitor serum theophylline levels. Use caution in patients with peptic ulcer, seizure disorders, cardiac arrhythmias, or hepatic impairment. Smoking and certain drugs alter metabolism.
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (unless on monitoring); uncontrolled seizure disorders; active peptic ulcer disease.
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
High-fat meals may delay absorption; take consistently with food to avoid fluctuations. Charcoal-grilled foods and a high-protein, low-carbohydrate diet can increase metabolism of theophylline, reducing efficacy. Avoid concurrent use with caffeine-containing foods/beverages due to additive CNS stimulation.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
BRONKODYL (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; animal studies show no consistent teratogenicity. Second and third trimesters: Possible fetal tachycardia and jitteriness with maternal high doses; risk of neonatal withdrawal if used near term.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Theophylline is excreted into breast milk with milk-to-plasma ratio approximately 0.60-0.70. Concentrations in milk are about 2/3 of maternal serum levels. Irritability and sleep disturbance reported in nursing infants; monitor infant for signs of caffeine-like effects.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
Pregnancy may increase elimination of theophylline, especially in the third trimester, requiring dose adjustment. Monitor levels; may need 20-30% higher dose in third trimester. Postpartum, clearance decreases rapidly; reduce dose to prepregnancy levels.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
BRONKODYL (theophylline) has a narrow therapeutic index; serum levels should be monitored (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer, seizure disorders, or uncontrolled arrhythmias. Cimetidine, ciprofloxacin, and macrolides increase theophylline levels; smoking and rifampin decrease them. Use with caution in heart failure, hepatic impairment, and in elderly patients, as clearance is reduced.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take this medication exactly as prescribed; do not double doses if missed.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, tremors, palpitations, or seizures.,Do not change brands or formulations without consulting your doctor, as bioavailability may differ.,Regular blood tests are necessary to monitor theophylline levels.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRONKODYL vs AEROLATE III, answered by our medical review team.
BRONKODYL is a Bronchodilator that works by Bronkodyl contains theophylline, a xanthine derivative. It acts as a bronchodilator by inhibiting phosphodiesterase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle. Additionally, it blocks adenosine receptors and may have anti-inflammatory effects.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRONKODYL and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRONKODYL is: Theophylline extended-release: 300-600 mg orally every 12 hours; target serum concentration 5-15 mcg/m L.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRONKODYL and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRONKODYL is classified as Category C. BRONKODYL (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; animal studies show no consistent teratogenicity. Second and third trimesters: Po. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.